 |
|
Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
February 03, 2006New system could replace time-intensive, century-old lab techniques
For the millions of people who suffer from urinary tract infections each year and the doctors who treat them, a promising new biosensor technology has been developed that may replace antiquated testing methods and save precious health care dollars.
In a recent clinical study conducted by the David Geffen School of Medicine at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System, researchers used a biosensor developed by corporate partner GeneFluidics to identify correctly the infection-causing gram negative bacteria species in 98 percent of the tested clinical urinary tract infection urine samples. These results represent the first ever species-specific detection of bacteria in human clinical fluid samples using a microfabricated electrochemical sensor array.
Of equal significance, the new test provided results in 45 minutes, compared to two days with conventional methods.
The research, reported in the February 2006 issue of the peer-reviewed Journal of Clinical Microbiology, investigated a new technology to solve an old problem: the diagnosis of urinary tract infections - the second most common bacterial infection - in a clinically relevant timeframe.
In current laboratory practice, contaminating pathogens in urine specimens are grown in culture dishes until they can be visually identified. The major drawback of this century-old technique is the two-day time lag between specimen collection and bacteria identification. As a result, physicians must decide whether to prescribe antibiotic therapy and, if so, which type of bacteria to treat - all without knowing the cause of the infection, if any. In contrast, the new biosensor technology would allow physicians to prescribe targeted treatment without the wait.
"Our research also showed that GeneFluidics' biosensor avoided problems inherent in alternative molecular approaches, such as PCR, that require the repeated copying of bacterial DNA or RNA prior to testing. We found that these amplification methods do not provide reproducible results," said lead author Dr. Joseph C. Liao, clinical instructor of urology at the David Geffen School of Medicine at UCLA.
The clinical study was performed at the VA Greater Los Angeles Healthcare System in the laboratory of Dr. David Haake, VA staff physician and professor of medicine at UCLA. Researchers studied samples received by the UCLA Clinical Microbiology Laboratory.
Individual sensors on GeneFluidics' 16-sensor chips were coated with UCLA-designed species-specific genetic probes. Clinical urine samples were directly applied to the chips and the electrochemical signal subsequently measured by GeneFluidics' multi-channel reader instrument. The urinary tract infection pathogens were identified by examining which signals on the sensor chip were elevated. The entire experiment from sample collection to result read-out took only 45 minutes.
The potential for rapid bacterial detection was discovered in the laboratory of Dr. Edward McCabe, chair of pediatrics at the Mattel Children's Hospital at UCLA and an adviser to GeneFluidics. McCabe's group demonstrated that probes could bind to species-specific bacterial sequences within minutes, rather than hours. These exciting results were translated to the biosensor protocol, leading to the development of the biosensor for rapid identification of bacteria in urine from patients with urinary tract infections.
"Results were impressive for this initial 78-sample clinical study," said Dr. Bernard Churchill, chief of pediatric urology at the Clark-Morrison Children's Urological Center at UCLA and principal investigator. "By coupling UCLA's robust probes with GeneFluidics' ultra sensitive biosensor system, we were able to identify urinary tract infection pathogens in a time frame that would enable physicians to make dramatically superior clinical decisions."
Ongoing work at UCLA and the VA Medical Center is focused on developing even better detection methods to bring the urinary tract infection biosensor chip from "bench to bedside." At GeneFluidics, engineers are integrating the biosensors into microfluidic cartridges and building a new instrument for faster and completely automated experimentation. The team anticipates the rapid test could become available in the next two to three years.
"There is considerable interest in decreasing overall health care costs by providing smarter medicine," added Dr. Vincent Gau, chief executive officer of GeneFluidics. "When laboratory-quality testing can be rapidly performed by anyone, anywhere, and the results made available in 'real-time,' we will see tremendous improvement in patient care. This joint project with UCLA may spearhead that shift."
Urinary tract infection is the most common urological disease in the United States and the most common bacterial infection of any organ system. Urinary tract infection is a major cause of patient death and health care expenditure for all age groups, accounting for more than 7 million office visits and more than 1 million hospital admissions per year. In the hospital, catheter associated urinary tract infection accounts for 40 percent of all in-hospital acquired infections - more than 1 million cases each year. The total cost of urinary tract infections to the United States health care system in 2000 was approximately 3.5 billion dollars.
The collaboration between UCLA, VA and GeneFluidics began in 2001, thanks to initial funding from Frank W. Clark Jr., and the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research.
Subsequently, the work has been supported by a $5.6 million Bioengineering Research Partnership grant from the National Institute of Biomedical Imaging and Bioengineering.
University of California-Los Angeles
Of equal significance, the new test provided results in 45 minutes, compared to two days with conventional methods.
The research, reported in the February 2006 issue of the peer-reviewed Journal of Clinical Microbiology, investigated a new technology to solve an old problem: the diagnosis of urinary tract infections - the second most common bacterial infection - in a clinically relevant timeframe.
In current laboratory practice, contaminating pathogens in urine specimens are grown in culture dishes until they can be visually identified. The major drawback of this century-old technique is the two-day time lag between specimen collection and bacteria identification. As a result, physicians must decide whether to prescribe antibiotic therapy and, if so, which type of bacteria to treat - all without knowing the cause of the infection, if any. In contrast, the new biosensor technology would allow physicians to prescribe targeted treatment without the wait.
"Our research also showed that GeneFluidics' biosensor avoided problems inherent in alternative molecular approaches, such as PCR, that require the repeated copying of bacterial DNA or RNA prior to testing. We found that these amplification methods do not provide reproducible results," said lead author Dr. Joseph C. Liao, clinical instructor of urology at the David Geffen School of Medicine at UCLA.
The clinical study was performed at the VA Greater Los Angeles Healthcare System in the laboratory of Dr. David Haake, VA staff physician and professor of medicine at UCLA. Researchers studied samples received by the UCLA Clinical Microbiology Laboratory.
Individual sensors on GeneFluidics' 16-sensor chips were coated with UCLA-designed species-specific genetic probes. Clinical urine samples were directly applied to the chips and the electrochemical signal subsequently measured by GeneFluidics' multi-channel reader instrument. The urinary tract infection pathogens were identified by examining which signals on the sensor chip were elevated. The entire experiment from sample collection to result read-out took only 45 minutes.
The potential for rapid bacterial detection was discovered in the laboratory of Dr. Edward McCabe, chair of pediatrics at the Mattel Children's Hospital at UCLA and an adviser to GeneFluidics. McCabe's group demonstrated that probes could bind to species-specific bacterial sequences within minutes, rather than hours. These exciting results were translated to the biosensor protocol, leading to the development of the biosensor for rapid identification of bacteria in urine from patients with urinary tract infections.
"Results were impressive for this initial 78-sample clinical study," said Dr. Bernard Churchill, chief of pediatric urology at the Clark-Morrison Children's Urological Center at UCLA and principal investigator. "By coupling UCLA's robust probes with GeneFluidics' ultra sensitive biosensor system, we were able to identify urinary tract infection pathogens in a time frame that would enable physicians to make dramatically superior clinical decisions."
Ongoing work at UCLA and the VA Medical Center is focused on developing even better detection methods to bring the urinary tract infection biosensor chip from "bench to bedside." At GeneFluidics, engineers are integrating the biosensors into microfluidic cartridges and building a new instrument for faster and completely automated experimentation. The team anticipates the rapid test could become available in the next two to three years.
"There is considerable interest in decreasing overall health care costs by providing smarter medicine," added Dr. Vincent Gau, chief executive officer of GeneFluidics. "When laboratory-quality testing can be rapidly performed by anyone, anywhere, and the results made available in 'real-time,' we will see tremendous improvement in patient care. This joint project with UCLA may spearhead that shift."
Urinary tract infection is the most common urological disease in the United States and the most common bacterial infection of any organ system. Urinary tract infection is a major cause of patient death and health care expenditure for all age groups, accounting for more than 7 million office visits and more than 1 million hospital admissions per year. In the hospital, catheter associated urinary tract infection accounts for 40 percent of all in-hospital acquired infections - more than 1 million cases each year. The total cost of urinary tract infections to the United States health care system in 2000 was approximately 3.5 billion dollars.
The collaboration between UCLA, VA and GeneFluidics began in 2001, thanks to initial funding from Frank W. Clark Jr., and the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research.
Subsequently, the work has been supported by a $5.6 million Bioengineering Research Partnership grant from the National Institute of Biomedical Imaging and Bioengineering.
University of California-Los Angeles
Urinary Tract Infection Current Events and Urinary Tract Infection News RSSDelirium in hospitalized adults: Situation critical, no relief available
Every year as many as seven million adults in the United States experience delirium during hospitalization.
Institute for Aging Research finds modifiable hip fracture complications contribute to mortality
Potentially modifiable post-fracture complications, including pneumonia and pressure ulcers, are associated with an increased risk of death among nursing home residents who have suffered a hip fracture, according to a new study conducted by scientists at the Institute for Aging Research at Hebrew SeniorLife.
Obesity associated with higher risk for urinary tract infections
As body mass increases, so does a patient's risk of urinary tract infection (UTI), according to Baltimore researchers. A new study, presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA) assesses and stratifies this risk.
Predominant risk factors for first urinary tract infections in college-aged women
Increased sexual activity and alcohol consumption were associated with an increased risk of developing urinary tract infections (UTIs), and college-aged women experiencing urinary frequency or urgency should seek medical care to treat what may be their first urinary tract infection (UTI), according to new research presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Autologous muscle-derived cells may treat stress urinary incontinence
Researchers have confirmed that transplanting autologous muscle-derived cells (AMDC) into the bladder is safe at a wide range of doses and significantly improves symptoms and quality of life in patients with stress urinary incontinence.
Hospital care varies greatly for children with urinary tract infections
More than 45,000 infants and children in the United States are hospitalized each year for urinary tract infections, but a new study reveals significant variability across hospitals in treatment and outcomes.
Why bladder cancer is deadlier for some
Bladder cancer is much more likely to be deadly for women and African-Americans, but the reasons long believed to explain the phenomenon account for only part of the differences for such patients compared to their white and male counterparts.
Sexually transmitted disease, urinary tract infections may be bad combination for birth defect Chances of gastroschisis increase fourf
Women who reported having both a sexually transmitted disease (STD) and urinary tract infection (UTI) just before or during early pregnancy were four times more likely to have babies with gastroschisis-a severe birth defect in which infants are born with their intestines and other internal organs outside the abdomen, University of Utah researchers report in the online British Medical Journal.
A rare diagnosis in the operation room: Kidney atrophy due to duplicated colon in an adult
Gastrointestinal congenital anomalies are rare entities in an adult patient. Commonly they are located in the upper gastrointestinal system and present with intestinal symptoms such as bleeding, obstruction and/or perforation of the intestine.
Catheter chaos: Hospitals lag in preventing common infection
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter. All of those will require antibiotics. A few may suffer life-threatening complications.
More Urinary Tract Infection Current Events and Urinary Tract Infection News Articles
 |
AZO Urinary Tract Infection Test Strips, 3-Count Boxes (Pack of 2) by AZO Contains 3 tests. Two tests in one! More effective than nitrite-only tests. Same UTI Test pads used by most doctors. Home UTI test. Fast and easy to use. Simply call your doctor with the results. AZO Test Strips home UTI test can detect if you have a urin |
 |
AZO Standard Urinary Pain Relief Tablets, 30-Count Boxes (Pack of 3) by AZO Extended supply. Value package. No. 1 Urinary pain reliever (among non-prescription products). Fast relief for urinary discomfort. Pain; Burning; Urgency. Phenazopyridine Hydrochloride 95 mg. No. 1 Ingredient prescribed by doctors. Nothing relieves urinar |
 |
AZO All Natural Concentrated Cranberry Tablets, 50-Count Boxes (Pack of 3) by AZO Now you can get the benefits of cranberry juice, to maintain a healthy urinary tract, without the tart taste, added sugar or calories.* AZO Cranberry tablets contain an all-natural concentrate from pure, fresh cranberries. When taken regularly, AZO Cranbe |
 |
The Patient's Encyclopaedia of Urinary Tract Infection, Sexual Cystitis and Interstitial Cystitis by Angela Kilmartin (Author), Geoffrey Chamberlain (Foreword) Classic urinary tract infection and inflammation has pain, frequency, bleeding, backache and /or fever in any order or combination. It is also known as cystitis. No figures are kept because it is so very common, but in the 25 years since Angela introduced self-help and prevention, attacks in the UK have dropped by 50% from their high in 1971 when they were over 25 million a year. The medical profession generally has not changed its treatments at all, still only offering antibiotics, poor quality urine sampling and futile trips to helpless urologists who may cause further procedural damage. |
 |
UTI Clear for Cystitis, Bladder infections and Urinary Tract Infections (UTI's) by Native Remedies UTI-Clear is a 100% safe, non-addictive, natural herbal remedy formulated by our team of natural health experts for urinary tract health. UTI-Clear can be used consistently to safely support ongoing health and systemic balance in the urinary system. UTI-Clear contains seven herbs selected for their supportive function in maintaining urinary tract health, normal urine flow, and sustained bladder health. The ingredients in UTI-Clear are selected to maintain the healthy functioning of the urinary system, thereby helping to maintain balanced urine flow, suitable pH in the bladder, consistent elimination of toxins, and routine, healthy performance. UTI-Clear can make all the difference to urinary tract health, without compromising health and without the risk of serious side effects. |
 |
Clear Tract Capsules 60 Capsules by Clear Tract Much in the same way cranberry works, ClearTract interferes with the ability for the bacteria to cling this is sometimes called the "anti-adherence effect" ClearTract takes this effect to a whole new level and accomplishes more than cranberry has ever been able to achieve. 10-50X stronger than Cranberry ! No yeast infection rebound Safe For Long Term Use No Drugs All Natural No Side Effects ClearTract contains D-Mannose can be faster and more effective, especially in dealing with chronic problems, and it doesn't have the side-effects or other problems associated with antibiotics. |
 |
Testmedica - Urinary Tract, 5 Test by Testmedica Testmedica - Urinary Tract, 5 Test |
 |
Urinary Tract Infections: Detection, Prevention, and Management by Calvin M. Kunin (Author) Ohio State University, Columbus. Text on the practical prevention and management of urinary tract infections, for physicians. Formerly entitled 'Detection, Prevention, and Management of Urinary Tract Infections' (1987). Softcover. DNLM: Urinary Tract Infections. |
 |
Nature's Plus - Ultra Cranberry 1000/Sust.Rel., 1000 mg, 60 tablets by Nature's Plus Ultra Cranberry 1000 Sustained Release by Nature's Plus 60 Tablets |
 |
PetAlive UTI-Free for Pet Bladder and Urinary Tract Health (20g) by PetAlive PetAlive UTI-Free is a selected combination of herbal and homeopathic ingredients specially formulated to safely and effectively treat the causes and the symptoms of urinary tract and bladder infections in pets. UTI-Free naturally treats the symptoms of UTI infections in pets; maintains urinary tract and bladder health and helps prevent recurring infections. |
| © 2009 BrightSurf.com |